A novel synthetic compound overcomes drug resistance on EGFR (T790M) and cancer stemness in human non-small cell lung cancer

被引：0
|
作者：
Pan, Pei Ying [1 ]
Chang, Chien-Jen [2 ]
Liu, Kuang-Kai [2 ]
Chan, Yu-Chi [2 ]
Chen, Yan-Ting [2 ]
Chao, Jui-I [2 ]
机构：
[1] Natl Chiao Tung Univ, Bioinformat & Syst Biol, Hsinchu, Taiwan
[2] Natl Chiao Tung Univ, Hsinchu, Taiwan
来源：
FASEB JOURNAL | 2017年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
lb181
引用
收藏
页数：1
相关论文
共 50 条
  • [31] AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
    Zhao, Ren
    Zhou, Shun
    Xia, Bing
    Zhang, Cui-ying
    Hai, Ping
    Zhe, Hong
    Wang, Yan-yang
    BMC CANCER, 2016, 16
  • [32] Combined Treatment with Epimedium koreanum Nakai Extract and Gefitinib Overcomes Drug Resistance Caused by T790M Mutation in Non-Small Cell Lung Cancer Cells
    Song, Jie
    Zhong, Rongling
    Huang, Houcai
    Zhang, Zhenhai
    Ding, Dongmei
    Yan, Hongmei
    Sun, E.
    Jia, Xiaobin
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2014, 66 (04): : 682 - 689
  • [33] Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFRL858R/T790M
    Xu, Jian
    Zhu, Guo-Yuan
    Cao, Dai
    Pan, Hao
    Li, Ying-Wei
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 115
  • [34] Circulating tumor cells and T790M in metastatic non-small cell lung cancer patients with EGFR mutations and acquired resistance to TKI
    Isobe, Kazutoshi
    Hata, Yoshinobu
    Sato, Keita
    Sugino, Keishi
    Sano, Go
    Sakamoto, Susumu
    Takai, Yujiro
    Shibuya, Kazutoshi
    Takagi, Keigo
    Homma, Sakae
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer
    Spence, Tara
    Perera, Sheron
    Weiss, Jessica
    Grenier, Sylvie
    Ranich, Laura
    Shepherd, Frances
    Stockley, Tracy L.
    JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (02) : 91 - 97
  • [36] EGFR T790M resistance mutation in non small-cell lung carcinoma
    Denis, Marc G.
    Vallee, Audrey
    Theoleyre, Sandrine
    CLINICA CHIMICA ACTA, 2015, 444 : 81 - 85
  • [37] Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance
    Wang, Ying
    Liu, Qiuyun
    Chen, Haojie
    You, Jun
    Peng, Bin
    Cao, Fanfan
    Zhang, Xue
    Chen, Qing
    Uzan, Georges
    Xu, Limin
    Zhang, Denghai
    ANTI-CANCER DRUGS, 2018, 29 (08) : 748 - 755
  • [38] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
  • [39] Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
    Li, Hang
    Hu, Haichuan
    Wang, Rui
    Pan, Yunjian
    Wang, Lei
    Li, Yuan
    Zhang, Yang
    Ye, Ting
    Zhang, Yiliang
    Li, Bin
    Shen, Lei
    Sun, Yihua
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2014, 7 : 513 - 524
  • [40] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Choo, Joan Rou-En
    Tan, Chee-Seng
    Soo, Ross A.
    TARGETED ONCOLOGY, 2018, 13 (02) : 141 - 156
12345